ATE477000T1 - Verfahren und immunmodulierende nukleinsäurezusammensetzungen zur vorbeugung und behandlungvon erkrankungen - Google Patents

Verfahren und immunmodulierende nukleinsäurezusammensetzungen zur vorbeugung und behandlungvon erkrankungen

Info

Publication number
ATE477000T1
ATE477000T1 AT03789883T AT03789883T ATE477000T1 AT E477000 T1 ATE477000 T1 AT E477000T1 AT 03789883 T AT03789883 T AT 03789883T AT 03789883 T AT03789883 T AT 03789883T AT E477000 T1 ATE477000 T1 AT E477000T1
Authority
AT
Austria
Prior art keywords
preventing
relates
treating diseases
nucleic acid
methods
Prior art date
Application number
AT03789883T
Other languages
English (en)
Inventor
Hideki Garren
Peggy P Ho
Lawrence Steinman
Original Assignee
Bayhill Therapeutics Inc
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayhill Therapeutics Inc, Univ Leland Stanford Junior filed Critical Bayhill Therapeutics Inc
Application granted granted Critical
Publication of ATE477000T1 publication Critical patent/ATE477000T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
AT03789883T 2002-11-21 2003-11-21 Verfahren und immunmodulierende nukleinsäurezusammensetzungen zur vorbeugung und behandlungvon erkrankungen ATE477000T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42864302P 2002-11-21 2002-11-21
PCT/US2003/037157 WO2004047734A2 (en) 2002-11-21 2003-11-21 Methods and immune modulatory nucleic acid compositions for preventing and treating disease

Publications (1)

Publication Number Publication Date
ATE477000T1 true ATE477000T1 (de) 2010-08-15

Family

ID=32393438

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03789883T ATE477000T1 (de) 2002-11-21 2003-11-21 Verfahren und immunmodulierende nukleinsäurezusammensetzungen zur vorbeugung und behandlungvon erkrankungen

Country Status (15)

Country Link
US (1) US7811813B2 (de)
EP (5) EP2329827A3 (de)
JP (2) JP4750419B2 (de)
CN (2) CN100546657C (de)
AT (1) ATE477000T1 (de)
AU (2) AU2003294400B2 (de)
CA (1) CA2507249A1 (de)
DE (1) DE60333786D1 (de)
DK (1) DK1569696T3 (de)
ES (1) ES2350576T3 (de)
IL (1) IL168715A (de)
NZ (1) NZ540276A (de)
PT (1) PT1569696E (de)
SI (1) SI1569696T1 (de)
WO (1) WO2004047734A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
JP4101888B2 (ja) * 1997-06-06 2008-06-18 ダイナバックス テクノロジーズ コーポレイション 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法
US8759305B2 (en) * 2004-09-01 2014-06-24 Dynavax Technologies Corporation Methods and compositions for inhibition of innate immune responses and autoimmunity
EP1902032A1 (de) * 2005-06-22 2008-03-26 Astex Therapeutics Limited Pharmazeutische verbindungen
WO2007147007A2 (en) * 2006-06-13 2007-12-21 Bayhill Therapeutics, Inc. Methods and immune modulatory nucleic acid compositions for preventing and treating disease
EP2073844A4 (de) * 2006-12-06 2011-06-01 Medimmune Llc Verfahren zur behandlung von systemischem lupus erythematodes
US20100261172A1 (en) * 2007-05-03 2010-10-14 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
JP2010526107A (ja) 2007-05-03 2010-07-29 メディミューン，エルエルシー 自己免疫疾患の自己抗体マーカー
EP2209896B1 (de) 2007-10-26 2017-03-01 Dynavax Technologies Corporation Verfahren und zusammensetzungen zur hemmung von immunantworten und autoimmunität
MX2011010050A (es) 2009-03-25 2011-12-14 Univ Texas Composiciones para estimulación de resistencia inmune innata de mamiferos a patógenos.
CN103153346A (zh) 2010-06-16 2013-06-12 戴纳瓦克斯技术公司 使用tlr7和/或tlr9抑制剂的治疗方法
SE535625C2 (sv) 2010-10-28 2012-10-16 Toleranzia Ab Nya kompositioner och förfaranden för behandling av autoimmuna och allergiska sjukdomar
US20130236453A1 (en) * 2012-03-12 2013-09-12 The Ohio State University Methods and Compositions for Modulating Acute Graft-versus-Host Disease using miR-155 Specific Inhibitors
WO2013160865A1 (en) 2012-04-26 2013-10-31 Toleranzia Ab Immunotolerizing fusion proteins for treatment of multiple sclerosis
US9228184B2 (en) * 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
US9868955B2 (en) 2012-09-29 2018-01-16 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
HRP20201710T1 (hr) 2016-11-01 2020-12-25 Novo Nordisk A/S Tolerogeno dna cjepivo
US11279745B2 (en) 2019-04-26 2022-03-22 Novo Nordisk A/S Tolerogenic DNA vaccine

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4425732A (en) 1981-06-17 1984-01-17 Kania Tadeusz E Animal trap
US4650675A (en) 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5218103A (en) 1988-05-26 1993-06-08 University Patents, Inc. Nucleoside thiophosphoramidites
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
PT772619E (pt) * 1994-07-15 2006-10-31 Univ Iowa Res Found Oligonucleotidos imunomoduladores
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5712258A (en) 1995-03-23 1998-01-27 The Trustees Of The University Of Pennsylvania Inotropic ADP and ATP analogues and their pharmaceutical compositions
US5939400A (en) 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
AU3225097A (en) 1996-06-03 1998-01-05 Auragen, Inc. Immunotherapy for autoimmune disease
AU4992197A (en) * 1996-10-11 1998-05-11 Regents Of The University Of California, The Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
JP4101888B2 (ja) * 1997-06-06 2008-06-18 ダイナバックス テクノロジーズ コーポレイション 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法
US6087341A (en) 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
US7030098B2 (en) * 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
AU2001229472A1 (en) * 2000-01-10 2001-07-24 Elim Biopharmaceuticals, Inc. Novel plasmid dna vectors
AU2001297693A1 (en) * 2000-12-08 2002-09-12 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
EP2322185A3 (de) * 2001-11-21 2011-08-10 The Board Of Trustees Of The Leland Stanford Junior University Polynukleotidtherapie
US20050002953A1 (en) * 2003-05-06 2005-01-06 Jens Herold SARS-coronavirus virus-like particles and methods of use
WO2005032482A2 (en) * 2003-10-03 2005-04-14 Bayhill Therapeutics, Inc. Treatment of demyelinating autoimmune disease with modified ordered peptides
US20100048679A1 (en) * 2006-06-13 2010-02-25 Bayhill Therapeutics, Inc. Polynucleotide therapy
EP2068866A4 (de) * 2006-07-24 2010-04-07 Biogen Idec Inc Verfahren zur förderung von myelinisierung, neuronalem überleben und oligodendrozytendifferenzierung mittels verabreichung von sp35- bzw. trka-antagonisten
WO2009099642A2 (en) * 2008-02-05 2009-08-13 The Board Of Trustees Of The Leland Stanford Junior University Proteomic analysis of active multiple sclerosis lesions

Also Published As

Publication number Publication date
EP1569696A4 (de) 2006-01-11
US7811813B2 (en) 2010-10-12
CN100546657C (zh) 2009-10-07
EP2329827A3 (de) 2011-07-13
IL168715A (en) 2011-09-27
EP1569696A2 (de) 2005-09-07
JP2011148801A (ja) 2011-08-04
EP2298360A2 (de) 2011-03-23
DK1569696T3 (da) 2010-11-15
US20050261215A1 (en) 2005-11-24
EP2322186A3 (de) 2011-07-13
SI1569696T1 (sl) 2010-12-31
JP2006514933A (ja) 2006-05-18
NZ540276A (en) 2007-12-21
DE60333786D1 (de) 2010-09-23
EP2298360A3 (de) 2011-07-13
EP2329827A2 (de) 2011-06-08
AU2003294400A1 (en) 2004-06-18
EP1569696B1 (de) 2010-08-11
PT1569696E (pt) 2010-11-11
JP4750419B2 (ja) 2011-08-17
WO2004047734A2 (en) 2004-06-10
CN1777447A (zh) 2006-05-24
EP2353614A1 (de) 2011-08-10
WO2004047734A3 (en) 2004-08-12
AU2009201102A1 (en) 2009-04-09
CN101955976A (zh) 2011-01-26
CA2507249A1 (en) 2004-06-10
EP2322186A2 (de) 2011-05-18
AU2003294400B2 (en) 2008-12-18
ES2350576T3 (es) 2011-01-25

Similar Documents

Publication Publication Date Title
ATE477000T1 (de) Verfahren und immunmodulierende nukleinsäurezusammensetzungen zur vorbeugung und behandlungvon erkrankungen
WO2003045316A3 (en) Polynucleotide therapy
DE69935507D1 (de) Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
WO2002006339A3 (en) Proteins and nucleic acids encoding same
CY1110353T1 (el) Ανοσορρυθμιστικοι ολιγοσακχαριτες
BRPI0407207A (pt) Método para tratar, prevenir e diagnosticar uma infecção por heliocobacter
WO2007147007A3 (en) Methods and immune modulatory nucleic acid compositions for preventing and treating disease
ATE497763T1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
WO2003055912A3 (en) Secreted proteins
GB0300718D0 (en) Proteins
ATE348161T1 (de) Fctrx genannte proteine und dafür kodierende nuklein säure
DE60137459D1 (de) Verfahren und zusammensetzungen zur behandlung oder prävention von bakteriellen infektionen
WO2005030985A3 (en) Use of amino acid sequences involved in the elongation of fatty acids in identifying and/or developing compounds for preventing and/or treating metabolic diseases
GB0230006D0 (en) Proteins
WO2002058716A3 (en) Treatment of inflammatory bowel disease using growth factors
WO2005005471A3 (en) Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
WO2004101618A3 (en) Progestin-yol002c-cgi-45 receptor-related proteins
WO2005019427A3 (en) Methods for diagnosing and treatment of conditions that alter phosphate transport in mammals
WO2004043353A3 (en) Compositions and methods for treating acute myeloid leukemia
MXPA05012414A (es) Proteina secretada similar a tnf.
WO2003054178A3 (en) Metalloprotease proteins
WO2004035626A8 (en) Alpha macroglobulin protein family members
WO2004026905A3 (en) Transporter/channel proteins
WO2002088341A3 (en) P450 proteins
WO2004041861A3 (en) Alpha macroglobulin family member

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1569696

Country of ref document: EP